A proprietary combination–phentermine (an appetite suppressant similar to an amphetamine) and topiramate (an anticonvulsant) medication formulated as an extended-release capsule, which is used with diet and exercise to manage obesity in patients with a BMI of 30 or more, or in patients with a BMI of 27 or more and one or more related co-morbidities–hypertension, type 2 diabetes and hypercholesterolaemia.
Adverse effects Paraesthesia, dry mouth, constipation, upper respiratory tract infection, nasopharyngitis, metabolic acidosis, tachycardia, headache. Also, foetal toxicity, suicidal ideation, mood and sleep disorders, cognitive impairment
Contraindications Pregnancy, glaucoma, hyperthyroidism
Proprietary names Qnexa, Vivus